A Green Manufacturing Route to Testosterone - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

A Green Manufacturing Route to Testosterone
A second-generation and green manufacturing process for testosterone provided economic and ecological benefits.


Pharmaceutical Technology
Volume 33, Issue 9

The development process demonstrated the viability of the improved testosterone process. A second-generation testosterone multidisciplinary implementation team, consisting of staff with expertise in bioprocessing, chemical synthesis, and engineering was formed to redefine the process agility and compile documentation for current good manufacturing practice documentation, including quality and safety. The next step was pilot-plant production of reduced-scale qualification lots. Full-scale implementation of the improved testosterone process was completed six months later. In all, the time for process development to laboratory scale to process validation for commercial manufacture was 13 months. The key benefits were as follows:

  • Reduced raw material usage and trimmed manufacturing time to produce testosterone products of equivalent to historic Pfizer standards
  • Reduced solvent use by 50%
  • Eliminated use of several hazardous materials and improved process safety. The reagent, Neat-DIBAL, which is highly pyrophoric was eliminated. As this material has the potential for rapid reactivity with water or air, it must be handled with specialized storage and transfer equipment.
  • Improved final recrystallization with regard to solvent usage
  • Reduced hazardous waste streams
  • Improved waste-stream recycling by 30%.

Other examples of green-chemistry at work

The improved route to testosterone is one example of Pfizer's application of green-chemistry principles. Some other examples are:

  • Reduced 65% of the total organic waste (3.5 million liters per year of methanol and tetrahydrofuran) and eliminated liquid nitrogen in one step in manufacturing atorvastatin, the API in Pfizer's Lipitor.
  • Avoided 5 million gallons of solvent per year and more than 150 tons of the nickel catalyst using a third-generation synthesis in the manufacture of pregabalin, the API in Lyrica.
  • Eliminated 25,000 tons of waste per year in the manufacture of voricanazole, the API in Vfend through a green-chemistry modification in the manufacturing process. The synthesis utilizes two highly innovative types of chemistry: an ultra-efficient synthesis of the key pyrimidinone intermediate and the development of a novel highly diastereoselective Reformatksy coupling reaction.

These examples show the technical and economic benefits of applying green-chemistry in API manufacturing.

Bill Kovats is director and team leader of continuous improvement at Pfizer Global Manufacturing in Kalamazoo, Michigan. Kenneth Ball* is marketing manager of fine chemicals at Pfizer CentreSource, tel. 269.833.4436,

*To whom all correspondence should be addressed.

For more on this topic, see "Green API Manufacturing."


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Source: Pharmaceutical Technology,
Click here